Track topics on Twitter Track topics that are important to you
Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Letrozole Tablets, USP in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with Letrozole Tablets, USP for a median of 60 months [see Clinical Studies (14.2, 14.3)].
Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].
The recommended dose of Letrozole Tablets, USP is one 2.5 mg tablet administered once a day, without regard to meals.
In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. The planned duration of treatment in the study was 5 years with 73% of the patients having completed adjuvant therapy. Treatment should be discontinued at relapse [see Clinical Studies (14.1)].
In the extended adjuvant setting, the optimal treatment duration with letrozole tablet is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration was 60 months. Seventy-one percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse [see Clinical Studies (14.2)].
In patients with advanced disease, treatment with letrozole tablet should continue until tumor progression is evident. [see Clinical Studies (14.4, 14.5)]
No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although letrozole tablet blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of letrozole tablet in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Warnings and Precautions (5.3)]. The recommended dose of letrozole tablet for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Letrozole tablet exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.
No dosage adjustment is required for patients with renal impairment if creatinine clearance is ≥10 mL/min. [see Clinical Pharmacology (12.3)].
2.5 mg tablets: dark yellow, coated, round, slightly biconvex, with beveled edges (debossed with “E126” on one side and plain on the other side).
Letrozole tablets may cause fetal harm when administered to a pregnant woman and the clinical benefit to premenopausal women with breast cancer has not been demonstrated. Letrozole tablet is contraindicated in women who are or may become pregnant. If Letrozole tablet is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. [see Use in Specific Populations (8.1)]
Use of Letrozole tablet may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Results of a substudy to evaluate safety in the adjuvant setting comparing the effect on lumbar spine (L2L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P<0.0001) [See Adverse reactions (6.1)]. Updated results from the BMD sub-study in the extended adjuvant setting demonstrated that at 2 years patients receiving letrozole had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group. The changes from baseline in lumbar spine BMD in letrozole and placebo treated groups were not significantly different [see Adverse Reactions (6.2)].
In the adjuvant trial the incidence of bone fractures at any time after randomization was 13.8% for letrozole and 10.5% for tamoxifen. The incidence of osteoporosis was 5.1% for letrozole and 2.7% for tamoxifen [See Adverse Reactions (6.1)]. In the extended adjuvant trial the incidence of bone fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo. The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo [see Adverse Reactions (6.3)].
Consideration should be given to monitoring serum cholesterol. In the adjuvant trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients. CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients. Also in the adjuvant setting, an increase of ≥1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%). Lipid lowering medications were required for 25% of patients on letrozole and 16% on tamoxifen [see Adverse Reactions (6.1)].
Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of letrozole experienced approximately twice the exposure to letrozole as healthy volunteers with normal liver function. Therefore, a dose reduction is recommended for this patient population. The effect of hepatic impairment on letrozole exposure in cancer patients with elevated bilirubin levels has not been determined. [see Dosage and Administration (2.5)]
Because fatigue, dizziness, and somnolence have been reported with the use of Letrozole tablet, caution is advised when driving or using machinery until it is known how the patient reacts to letrozole use.
No dose-related effect of letrozole on any hematologic or clinical chemistry parameter was evident. Moderate decreases in lymphocyte counts, of uncertain clinical significance, were observed in some patients receiving Letrozole tablets 2.5 mg. This depression was transient in about half of those affected. Two patients on Letrozole tablets developed thrombocytopenia; relationship to the study drug was unclear. Patient withdrawal due to laboratory abnormalities, whether related to study treatment or not, was infrequent.
The most serious adverse reactions from the use of letrozole tablets are:
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The median treatment duration of adjuvant treatment was 60 months and the median duration of follow-up for safety was 73 months for patients receiving letrozole tablets and tamoxifen.
Certain adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs.
Adverse reactions were analyzed irrespective of whether a symptom was present or absent at baseline. Most adverse reactions reported (approximately 75% of patients reporting 1 or more AE) were Grade 1 or Grade 2 applying the Common Toxicity Criteria Version 2.0/ Common Terminology Criteria for Adverse Events, version 3.0. Table 1 describes adverse reactions (Grades 1-4) irrespective of relationship to study treatment in the adjuvant trial for the monotherapy arms analysis (safety population).
When considering all grades during study treatment, a higher incidence of events was seen for letrozole tablets regarding fractures (10.1% vs 7.1%), myocardial infarctions (1.0% vs 0.5%), and arthralgia (25.2% vs 20.4%) (letrozole tablets vs tamoxifen respectively). A higher incidence was seen for tamoxifen regarding thromboembolic events (2.1% vs 3.6%), endometrial hyperplasia/cancer (0.3% vs 2.9%), and endometrial proliferation disorders (0.3% vs 1.8%) (letrozole tablets vs tamoxifen respectively).
At a median follow up of 73 months, a higher incidence of events was seen for letrozole tablets (13.8%) than for tamoxifen (10.5%) regarding fractures. A higher incidence was seen for tamoxifen compared to letrozole tablets regarding thromboembolic events (4.5% vs 2.9%), and endometrial hyperplasia or cancer (2.9% vs 0.4%) (tamoxifen vs letrozole tablets, respectively).
Bone Study: Results of a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P<0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm.
Lipid Study: In a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen.
|Grades 1-4||Grades 3-4|
|Adverse Reaction|| Letrozole
N=2448 n (%)
N=2447 n (%)
N=2448 n (%)
N=2447 n (%)
|Pts with any adverse event||2310 (94.4)||2214 (90.5)||635 (25.9)||604 (24.7)|
|Hypercholesterolemia||1280 (52.3)||700 (28.6)||11 ( 0.4)||6 ( 0.2)|
|Hot Flashes/Flushes||821 (33.5)||929 (38.0)||0 -||0 -|
|Arthralgia/Arthritis||618 (25.2)||501 (20.4)||85 ( 3.5)||50 ( 2.0)|
|Night Sweats||357 (14.6)||426 (17.4)||0 -||0 -|
|Bone Fractures2||338 (13.8)||257 (10.5)||- -||- -|
|Weight Increase||317 (12.9)||378 (15.4)||27 ( 1.1)||39 ( 1.6)|
|Nausea||283 (11.6)||277 (11.3)||6 ( 0.2)||9 ( 0.4)|
|Bone Fractures1||247 (10.1)||174 ( 7.1)||- -||- -|
|Fatigue (Lethargy, Malaise, Asthenia)||235 ( 9.6)||250 (10.2)||6 ( 0.2)||7 ( 0.3)|
|Myalgia||217 ( 8.9)||212 ( 8.7)||18 ( 0.7)||14 ( 0.6)|
|Edema||164 ( 6.7)||160 ( 6.5)||3 ( 0.1)||1 (<0.1)|
|1 During study treatment, based on Safety Monotherapy population|
|2 Any time after randomization, including post treatment follow-up|
|3 Excluding women who had undergone hysterectomy before study entry|
|Note: Cardiovascular (including cerebrovascular and thromboembolic), skeletal and urogenital/endometrial events and second malignancies were collected life-long. All of these events were assumed to be of CTC grade 3-5 and were not individually graded.|
|Grades 1-4||Grades 3-4|
|Adverse Reaction|| Letrozole
N=2448 n (%)
N=2447 n (%)
N=2448 n (%)
N=2447 n (%)
|Weight Decrease||140 ( 5.7)||129 ( 5.3)||8 ( 0.3)||5 ( 0.2)|
|Vaginal Bleeding||128 ( 5.2)||320 (13.1)||1 (<0.1)||8 ( 0.3)|
|Back Pain||125 ( 5.1)||136 ( 5.6)||7 ( 0.3)||11 ( 0.4)|
|Osteoporosis NOS||124 ( 5.1)||66 ( 2.7)||10 ( 0.4)||5 ( 0.2)|
|Bone pain||123 ( 5.0)||109 ( 4.5)||6 ( 0.2)||4 ( 0.2)|
|Depression||119 ( 4.9)||114 ( 4.7)||16 ( 0.7)||14 ( 0.6)|
|Vaginal Irritation||111 ( 4.5)||77 ( 3.1)||2 (<0.1)||2 (<0.1)|
|Headache||105 ( 4.3)||94 ( 3.8)||9 ( 0.4)||5 ( 0.2)|
|Pain in extremity||103 ( 4.2)||79 ( 3.2)||6 ( 0.2)||4 ( 0.2)|
|Osteopenia||87 ( 3.6)||74 ( 3.0)||0 -||2 (<0.1)|
|Dizziness/Light-Headedness||84 ( 3.4)||84 ( 3.4)||1 (<0.1)||6 (0.2)|
|Alopecia||83 ( 3.4)||84 ( 3.4)||0 -||0 -|
|Vomiting||80 ( 3.3)||80 ( 3.3)||3 ( 0.1)||5 (0.2)|
|Cataract||49 ( 2.0)||54 ( 2.2)||16 ( 0.7)||17 ( 0.7)|
|Constipation||49 ( 2.0)||71 ( 2.9)||3 ( 0.1)||1 (<0.1)|
|Breast pain||37 ( 1.5)||43 ( 1.8)||1 (<0.1)||0 -|
|Anorexia||20 ( 0.8)||20 ( 0.8)||1 (<0.1)||1 (<0.1)|
|Endometrial Hyperplasia/ Cancer2, 3||11/1909 ( 0.6)||70/1943 ( 3.6)||- -||- -|
|Endometrial Proliferation Disorders||10 (0.3)||71 (1.8)||0 -||14 (0.6)|
|Endometrial Hyperplasia/ Cancer1, 3||6/1909 ( 0.3)||57/1943 (2.9)||- -||- -|
|Other Endometrial Disorders||2 (<0.1)||3 ( 0.1)||0 -||0 -|
|Myocardial Infarction1||24 ( 1.0)||12 ( 0.5)||- -||- -|
|Myocardial Infarction2||37 ( 1.5)||25 (1.0)||- -||- -|
|Myocardial Ischemia||6 ( 0.2)||9 ( 0.4)||- -||- -|
|Cerebrovascular Accident1||52 ( 2.1)||46 ( 1.9)||- -||- -|
|Cerebrovascular Accident2||70 ( 2.9)||63 ( 2.6)||- -||- -|
|Angina1||26 ( 1.1)||24 ( 1.0)||- -||- -|
|Angina2||32 ( 1.3)||31 ( 1.3)||- -||- -|
|Thromboembolic Event1||51 ( 2.1)||89 ( 3.6)||- -||- -|
|Thromboembolic Event2||71 ( 2.9)||111 ( 4.5)||- -||- -|
|Other Cardiovascular1||260 (10.6)||256 (10.5)||- -||- -|
|Other Cardiovascular2||312 (12.7)||337 (13.8)||- -||- -|
|Second Malignancies1||53 ( 2.2)||78 ( 3.2)||- -||- -|
|Second Malignancies2||102 ( 4.2)||119 ( 4.9)||- -||- -|
The median duration of extended adjuvant treatment was 24 months and the median duration of follow-up for safety was 28 months for patients receiving letrozole tablets and placebo.
Table 2 describes the adverse reactions occurring at a frequency of at least 5% in any treatment group during treatment. Most adverse reactions reported were Grade 1 and Grade 2 based on the Common Toxicity Criteria Version 2.0. In the extended adjuvant setting, the reported drug-related adverse reactions that were significantly different from placebo were hot flashes, arthralgia/arthritis, and myalgia.
Based on a median follow-up of patients for 28 months, the incidence of clinical fractures from the core randomized study in patients who received letrozole tablets was 5.9% (152) and placebo was 5.5% (142). The incidence of self-reported osteoporosis was higher in patients who received letrozole tablets 6.9% (176) than in patients who received placebo 5.5% (141). Bisphosphonates were administered to 21.1% of the patients who received letrozole tablets and 18.7% of the patients who received placebo.
The incidence of cardiovascular ischemic events from the core randomized study was comparable between patients who received letrozole tablets 6.8% (175) and placebo 6.5% (167).
A patient-reported measure that captures treatment impact on important symptoms associated with estrogen deficiency demonstrated a difference in favor of placebo for vasomotor and sexual symptom domains.
Bone Sub-study: [see Warnings and Precautions (5.1)].
Lipid Sub-study: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between letrozole tablets and placebo in total cholesterol or in any lipid fraction at any time over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed. [see Warnings and Precautions (5.2)].
| Number (%) of Patients
with Grade 1-4 Adverse
| Number (%) of Patients
with Grade 3-4 Adverse
|Any Adverse Reaction||2232 (87.1)||2174 (84.5)||419 (16.3)||389 (15.1)|
|Vascular Disorders||1375 (53.6)||1230 (47.8)||59 (2.3)||74 (2.9)|
|Flushing||1273 (49.7)||1114 (43.3)||3 (0.1)||0 -|
|General Disorders||1154 (45)||1090 (42.4)||30 (1.2)||28 (1.1)|
|Asthenia||862 (33.6)||826 (32.1)||16 (0.6)||7 (0.3)|
|Edema NOS||471 (18.4)||416 (16.2)||4 (0.2)||3 (0.1)|
|Musculoskeletal Disorders||978 (38.2)||836 (32.5)||71 (2.8)||50 (1.9)|
|Arthralgia||565 (22)||465 (18.1)||25 (1)||20 (0.8)|
|Arthritis NOS||173 (6.7)||124 (4.8)||10 (0.4)||5 (0.2)|
|Myalgia||171 (6.7)||122 (4.7)||8 (0.3)||6 (0.2)|
|Back Pain||129 (5)||112 (4.4)||8 (0.3)||7 (0.3)|
|Nervous System Disorders||863 (33.7)||819 (31.8)||65 (2.5)||58 (2.3)|
|Headache||516 (20.1)||508 (19.7)||18 (0.7)||17 (0.7)|
|Dizziness||363 (14.2)||342 (13.3)||9 (0.4)||6 (0.2)|
|Skin Disorders||830 (32.4)||787 (30.6)||17 (0.7)||16 (0.6)|
|Sweating Increased||619 (24.2)||577 (22.4)||1 (<0.1)||0 -|
|Gastrointestinal Disorders||725 (28.3)||731 (28.4)||43 (1.7)||42 (1.6)|
|Constipation||290 (11.3)||304 (11.8)||6 (0.2)||2 (<0.1)|
|Nausea||221 (8.6)||212 (8.2)||3 (0.1)||10 (0.4)|
|Diarrhea NOS||128 (5)||143 (5.6)||12 (0.5)||8 (0.3)|
|Metabolic Disorders||551 (21.5)||537 (20.9)||24 (0.9)||32 (1.2)|
|Hypercholesterolemia||401 (15.6)||398 (15.5)||2 (<0.1)||5 (0.2)|
|Reproductive Disorders||303 (11.8)||357 (13.9)||9 (0.4)||8 (0.3)|
|Vaginal Hemorrhage||123 (4.8)||171 (6.6)||2 (<0.1)||5 (0.2)|
|Vulvovaginal Dryness||137 (5.3)||127 (4.9)||0 -||0 -|
|Psychiatric Disorders||320 (12.5)||276 (10.7)||21 (0.8)||16 (0.6)|
|Insomnia||149 (5.8)||120 (4.7)||2 (<0.1)||2 (<0.1)|
|Respiratory Disorders||279 (10.9)||260 (10.1)||30 (1.2)||28 (1.1)|
|Dyspnea||140 (5.5)||137 (5.3)||21 (0.8)||18 (0.7)|
|Investigations||184 (7.2)||147 (5.7)||13 (0.5)||13 (0.5)|
|Infections and Infestations||166 (6.5)||163 (6.3)||40 (1.6)||33 (1.3)|
|Renal Disorders||130 (5.1)||100 (3.9)||12 (0.5)||6 (0.2)|
The extended adjuvant treatment trial was unblinded early [see Adverse Reactions (6.2)]. At the updated (final analysis), overall the side effects seen were consistent to those seen at a median treatment duration of 24 months.
During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) a higher rate of fractures was observed for letrozole tablets (10.4%) compared to placebo (5.8%), as also a higher rate of osteoporosis (letrozole tablets 12.2% vs placebo 6.4%).
Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of new fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo. The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo. During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) the incidence of cardiovascular events was 9.8% for letrozole tablets and 7.0% for placebo.
Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of cardiovascular disease at any time after randomization was 14.4% for letrozole and 9.8% for placebo.
Lipid sub-study: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between letrozole and placebo in total cholesterol or in any lipid fraction over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed. [see Warnings and Precautions(5.2)]
A total of 455 patients were treated for a median time of exposure of 11 months. The incidence of adverse reactions was similar for letrozole and tamoxifen. The most frequently reported adverse reactions were bone pain, hot flushes, back pain, nausea, arthralgia and dyspnea. Discontinuations for adverse reactions other than progression of tumor occurred in 10/455 (2%) of patients on letrozole tablets and in 15/455 (3%) of patients on tamoxifen.
Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole tablets 2.5 mg or tamoxifen 20 mg in the first-line treatment study are shown in Table 3.
Other less frequent (≤2%) adverse reactions considered consequential for both treatment groups, included peripheral thromboembolic events, cardiovascular events, and cerebrovascular events. Peripheral thromboembolic events included venous thrombosis, thrombophlebitis, portal vein thrombosis and pulmonary embolism. Cardiovascular events included angina, myocardial infarction, myocardial ischemia, and coronary heart disease. Cerebrovascular events included transient ischemic attacks, thrombotic or hemorrhagic strokes and development of hemiparesis.
|Urinary Tract Infection NOS||6||3|
|Injury, Poisoning and Procedural Complications|
|Metabolism and Nutrition Disorders|
|Musculoskeletal and Connective Tissue Disorders|
|Pain in Limb||10||8|
|Nervous System Disorders|
|Reproductive System and Breast Disorders|
|Respiratory, Thoracic and Mediastinal Disorders|
|Chest Wall Pain||6||6|
Study discontinuations in the megestrol acetate comparison study for adverse reactions other than progression of tumor were 5/188 (2.7%) on letrozole 0.5 mg, in 4/174 (2.3%) on letrozole 2.5 mg, and in 15/190 (7.9%) on megestrol acetate. There were fewer thromboembolic events at both letrozole doses than on the megestrol acetate arm (0.6% vs 4.7%). There was also less vaginal bleeding (0.3% vs 3.2%) on letrozole than on megestrol acetate. In the aminoglutethimide comparison study, discontinuations for reasons other than progression occurred in 6/193 (3.1%) on 0.5 mg letrozole, 7/185 (3.8%) on 2.5 mg letrozole, and 7/178 (3.9%) of patients on aminoglutethimide.
These highlights do not include all the information needed to use Letrozole Tablets, USP safely and effectively. See full prescribing information for Letrozole Tablets, USP Letrozole Tablets, USPIniti...
These highlights do not include all the information needed to use letrozole tablets safely and effectively. See full prescribing information for letrozole tablets.Letrozole tablets USP, 2.5 mgInitial ...
These highlights do not include all the information needed to use letrozole safely and effectively. See full prescribing information for letrozole tablets. Letrozole Tablets, USPInitial U.S. Approval:...
These highlights do not include all the information needed to use letrozole tablets safely and effectively. See full prescribing information for letrozole tablets. LETROZOLE Tablets, USPInitial U.S. A...
These highlights do not include all the information needed to use letrozole safely and effectively. See full prescribing information for letrozole tablets. Letrozole Tablets, USP Initial U.S. Approval...
PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with sympto...
The goal of the study is to measure serial hormonal levels in patients undergoing clomiphene, letrozole, and a combination clomiphene and letrozole cycle. This information may help us to ...
This randomized phase 2 trial is evaluating superiority of Letrozole-palbociclib combination versus letrozole alone in ER positive endometrioid adenocarcinoma of endometrium
This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the effect of combining letrozole and GDC-0032 versus letrozole and placebo in postmenopausal wome...
This is a phase 2 study of bosutinib administered in combination with letrozole versus letrozole alone in post-menopausal women with breast cancer. This is a 2-part study. Subjects in part...
A Retrospective Study of Letrozole Treatment Prior to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization at Risk of Ovarian Hyperstimulation Syndrome.
BACKGROUND Women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) are given letrozole before a trigger injection of human chorionic gonadotropin (hCG) to lower estrogen (E...
Polycystic ovary syndrome (PCOS) is an endocrine disorder in women of reproductive age. In addition to anovulation, endometrial dysfunction can reduce fertility in PCOS. The cyclical changes of endome...
Letrozole is an aromatase inhibitor with an unapproved use for ovulation induction with infertility. Because of the proximity of this use to conception, we selected letrozole to explore the effect of ...
Evidence shows neurosteroids play a key role in regulating epileptogenesis. Neurosteroids such as testosterone modulate seizure susceptibility through its transformation to metabolites which show proc...
The aim of the study was to evaluate the incidence of congenital fetal anomalies reported among infertile Iranian women treated with letrozole compared to those treated with Clomiphene Citrate (CC).
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...